3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Disease Models

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) with an IC50 of ~50 nM in CHO cells, offering robust and selective inhibition of PARP activity at micromolar concentrations with low cytotoxicity (Grunewald et al., 2019). It enables more than 95% inhibition of PARP at >1 μM, supports research into oxidant-induced myocyte dysfunction, and improves endothelial function by modulating nitric oxide-mediated vasorelaxation. In diabetic nephropathy models, 3-Aminobenzamide reduces albuminuria, mesangial expansion, and podocyte depletion, supporting its translational relevance. APExBIO supplies this compound under SKU A4161 for research use only (APExBIO).

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes responsible for ADP-ribosylation, a reversible post-translational modification that regulates DNA repair, chromatin structure, and cellular stress responses (Grunewald et al., 2019). Humans encode 17 PARPs, with PARP1 and PARP2 playing central roles in poly-ADP-ribosylation (PARylation). Dysregulation of PARP activity is implicated in pathologies such as ischemia-reperfusion injury, diabetes-induced organ damage, and viral infection. Inhibiting PARP enzymatic function can modulate these disease processes, making PARP inhibitors key tools in experimental models and drug discovery (Mechanistic Insights and Strategy). This article extends mechanistic details and translational context beyond prior overviews by focusing on atomic evidence and practical workflow integration.

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide (C₇H₈N₂O; MW 136.15; CAS: 3544-24-9) is a competitive inhibitor of PARP enzymes. It binds to the NAD⁺ site on PARP1 and PARP2, blocking the transfer of ADP-ribose units to substrate proteins (Grunewald et al., 2019). This inhibition prevents the formation of poly(ADP-ribose) chains, halting downstream signaling involved in DNA repair and stress response. In cellular models such as CHO cells, 3-Aminobenzamide achieves 50% inhibition of PARP activity (IC50) at approximately 50 nM, while complete inhibition (>95%) is observed at concentrations above 1 μM without significant cytotoxicity. This selectivity enables precise modulation of ADP-ribosylation-dependent processes (Potent PARP Inhibitor in Benchmarking).

Evidence & Benchmarks

• 3-Aminobenzamide (PARP-IN-1) inhibits poly (ADP-ribose) polymerase activity in CHO cells with an IC50 of ~50 nM, allowing quantifiable PARP activity inhibition assays (Grunewald et al., 2019).
• At concentrations >1 μM, 3-Aminobenzamide achieves >95% PARP inhibition in vitro without significant cytotoxicity (APExBIO product page).
• The compound significantly improves endothelium-dependent, nitric oxide-mediated vasorelaxation after oxidative stress in ex vivo vascular assays (Chempaign: Disease Model Application).
• In diabetic db/db mouse models, 3-Aminobenzamide reduces albumin excretion, mesangial expansion, and podocyte depletion, indicating protection against diabetic nephropathy (Mechanistic Insights).
• PARP inhibition with 3-Aminobenzamide modulates interferon production and viral replication in primary macrophages by blocking PARP12/14 activity (Grunewald et al., 2019).
• The compound is soluble at ≥23.45 mg/mL in water, ≥48.1 mg/mL in ethanol, and ≥7.35 mg/mL in DMSO, supporting various assay formats (APExBIO).

This article integrates new evidence on immunomodulation and viral pathogenesis, clarifying and expanding on the practical use cases discussed in prior benchmarking articles.

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely used in preclinical research to dissect PARP-dependent processes:

• Oxidant-induced myocyte dysfunction during ischemia-reperfusion studies.
• Endothelial function analysis via acetylcholine-mediated vasorelaxation in vascular tissues.
• Diabetic nephropathy modeling in db/db mice, particularly for podocyte depletion and glomerular injury endpoints.
• Cellular stress response and DNA repair research.
• Immune modulation studies, including interferon induction and viral replication restriction (Grunewald et al., 2019).

Unlike some PARP inhibitors, 3-Aminobenzamide is not designed for clinical use and should not be applied in diagnostic or therapeutic contexts (APExBIO).

Common Pitfalls or Misconceptions

• 3-Aminobenzamide does not inhibit all ADP-ribosyltransferases; its activity is specific to PARP1/2 and closely related isoforms.
• It is not suitable for long-term solution storage; stock solutions should be prepared fresh or stored short-term at -20°C (APExBIO).
• The compound is not intended for clinical or diagnostic applications and is for research use only.
• High concentrations (>10 μM) may interfere with off-target enzymes in some cell types, necessitating titration for specificity controls.
• PARP inhibition does not equate to complete blockade of all DNA repair pathways; redundancy exists via other repair mechanisms.

Workflow Integration & Parameters

For robust and reproducible results, the following guidelines should be applied when using 3-Aminobenzamide (PARP-IN-1):

• Prepare fresh stock solutions in water, ethanol, or DMSO using ultrasonic assistance to achieve solubility thresholds (water: ≥23.45 mg/mL, ethanol: ≥48.1 mg/mL, DMSO: ≥7.35 mg/mL).
• Store solid compound at -20°C. Avoid repeated freeze-thaw cycles of solutions.
• Apply at concentrations of 50 nM to 10 μM for PARP inhibition assays; verify cellular toxicity using viability assays.
• Include appropriate vehicle controls (matching solvent concentration) in all experiments.
• Reference internal guides, such as this cell viability workflow article, for scenario-driven best practices; this article expands with new immunological and disease model data.

For product details and ordering, visit the 3-Aminobenzamide (PARP-IN-1) product page from APExBIO.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) remains a gold-standard tool for dissecting poly (ADP-ribose) polymerase inhibition in basic and translational research. Its well-characterized mechanism, favorable solubility, and low toxicity profile make it suitable for cellular and animal models of oxidative stress, endothelial dysfunction, and diabetic nephropathy. Recent findings highlight its role in immune modulation and viral pathogenesis, underscoring its continued relevance for emerging disease models. For further mechanistic and translational perspectives, see this advanced insights article, which is extended with new data here. Researchers are encouraged to follow assay-specific best practices to maximize reproducibility and data integrity.